Albert Einstein Comprehensive Cancer Center

Summary

Albert Einstein Comprehensive Cancer Center is a medical facility located in Bronx, New York. This center is recognized for care of Breast Cancer, Leukemia, Lymphoma, Lung Cancer, Brain Tumor and other specialties. Albert Einstein Comprehensive Cancer Center is involved with conducting 225 clinical trials across 187 conditions. There are 5 research doctors associated with this hospital, such as Sanjay Goel, Ioannis Mantzaris, MD, Beth N. Mclellan, MD, and Anna Ferrari, MD.

Top PIs

Clinical Trials running at Albert Einstein Comprehensive Cancer Center

Solid Tumors

Small Cell Lung Cancer

Myelodysplastic Syndrome

Myelofibrosis

Lung Cancer

Breast Cancer

Acute Myelogenous Leukemia

Acute Myeloid Leukemia

Blood Disorders

Childhood Blood Disease

DF1001

for Solid Cancers

This trial is testing a new treatment called DF1001-001 that helps the immune system target and destroy cancer cells. It focuses on patients with certain types of cancers that have a protein called HER2. The treatment works by activating immune cells to recognize and attack these cancer cells.

Recruiting

1 award

Phase 1 & 2

52 criteria

Targeted Therapy + Immunotherapy

for Advanced Cancer

TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.

Recruiting

1 award

Phase 2

12 criteria

AN4005

for Advanced Cancer

This trial tests a new drug, AN4005, in patients with advanced tumors. It aims to find the highest safe dose by adjusting the amount given over time.

Recruiting

1 award

Phase 1

10 criteria